Innate Pharma (IPHA) Net Margin (2019 - 2024)
Innate Pharma (IPHA) posted quarterly Net Margin of 391.94% for Q4 2024, down 37736.0% year-on-year from N/an in Q1 2024, and down 31.25% on a QoQ basis from 298.61% in Q2 2024.
Innate Pharma (IPHA) Net Margin (2019 - 2024) Analysis & Trends
Innate Pharma (IPHA) has reported Net Margin for 6 consecutive years, with 391.94% the latest figure, recorded in Q4 2024.
- Quarterly Net Margin fell 37736.0% year-over-year to 391.94% in Q4 2024, while the trailing twelve-month figure through Dec 2025 was 126.42% (down 4863.0% YoY) and the FY2025 annual result came in at 241.02%, down 28493.0% from the prior year.
- Net Margin retreated to 391.94% in Q4 2024 per IPHA's latest filing, from 298.61% in the prior quarter.
- Over the last five years, Net Margin for IPHA reached as high as 887.05% in Q4 2021 and fell as low as 391.94% in Q4 2024.
- A 5-year average of 7.82% and a median of 10.59% in 2023 frame the typical range for Net Margin.
- Annual changes were most pronounced in 2021 — Net Margin soared 99952 bps — and 2022, when it tumbled 88694 bps.
- Year by year, Net Margin stood at 112.47% in 2020, then jumped by 889 bps to 887.05% in 2021, then sank by 100 bps to 0.11% in 2022, then slumped by 13454 bps to 14.59% in 2023, then sank by 2587 bps to 391.94% in 2024.
- According to Business Quant data, Net Margin over the past three periods registered 391.94%, 298.61%, and 14.59% for Q4 2024, Q2 2024, and Q4 2023 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 15.02% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 34.53% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 20.17% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 30.33% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Innate Pharma | 157.68 Mn | 157.68 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -391.94% |
| Jun 30, 2024 | -298.61% |
| Dec 31, 2023 | -14.59% |
| Jun 30, 2023 | -6.59% |
| Dec 31, 2022 | 0.11% |
| Jun 30, 2022 | -0.42% |
| Dec 31, 2021 | 887.05% |
| Dec 31, 2020 | -112.47% |
| Dec 31, 2019 | -30.10% |